Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Slides:

Advertisements

Similar presentations

Role of Nursing in the Continuum of Inpatient Diabetes Care

Advertisements

University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

MODELING METHOD Glucose-Insulin System Model CLINICAL DATA DATA: Are taken from the SPRINT [3] TGC cohort totalling 393 patients and ~40,000 patient hours.

Canadian Diabetes Association Clinical Practice Guidelines In-Hospital Management of Diabetes Chapter 16 Robyn Houlden, Sara Capes, Maureen Clement, David.

Treatment of diabetes mellitus in hospitals Done by: Fatimah Al-Shehri Pharm.D Candidate King Abdulaziz university Supervised by: Dr.Hani Hassan Clinical.

Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Featured Article: Michaela Diamant, Michael A.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

INPATIENT DIABETES GUIDE Ananda Nimalasuriya M.D..

4-07 CHANGE IS GOOD: THE BASAL BOLUS INSULIN CONCEPT Management of Hyperglycemia in the Adult Hospitalized Patient: Admission to Discharge TEAM MEMBERS:

Management of Inpatient Blood Glucose at Temple Housestaff Orientation 2014.

Diabetes Technology Update

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

L.M. Fisk, A.J. Le Compte, G.M. Shaw, S. Penning, T. Desaive, J.G. Chase Pilot Trial of STAR in Medical ICU INTRODUCTION Background: Accurate glycemic.

MANAGEMENT OF THE HOSPITALIZED TYPE I DIABETIC PATIENT Riverside Methodist Hospital January 23, 2014 Rundsarah Tahboub, MD.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

New Insulin Formulations

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.

Metabolic Effects of Bariatric Surgery

Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCOCABG Trial.

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Toujeo® and it’s Place in Therapy

K. Ann Caudell, PhD, ACNP - BC. * Identify patients with out-of-range CBGs * Assist in maintaining CBGs between 80 mg/dL & 180 mg/dL during hospitalization.

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.

PowerHour Information 03/09/2011.  Background  Description  Vision  Mission  Measurements  Participation Requirements.

Effectiveness of Early Intensive Therapy On β-Cell Preservation in Type 1 Diabetes Featured Article: Bruce Buckingham, M.D., Roy W. Beck, M.D., P.H.D.,

Endocrine and Metabolic Disorders Lectures 8 I.Kuziv, MD, PhD.

New Insulin Formulations

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free- Living, Randomized Clinical Trial Featured Article: Roman Hovorka,

Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Insulin Initiation With NovoMix30

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Intensive Versus Intermediate Glucose Control in Surgical Intensive Care Unit Patients Featured Article: Takehiro Okabayashi, Yasuo Shima,Tatsuaki Sumiyoshi,

Achieving Glycemic Control in the Hospital Setting

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial Yves.

Special Situations In The Management Of In-Patient Hyperglycemia

Strategies to Reduce Hypoglycemia Presented by: Hennie Garza, M.S., R.Ph., C.D.E, Director of Pharmacy Utilization and Outcomes Senior Care Centers

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Review of Recent Developments in Context Greg Maynard MD, MSc

Pharmacy Protocol for Insulin Dosing in the Hospitalized Patient

Mastery of Medicine in Diabetes Management Video Roundtable

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Key publication slides

New Patient-Friendly Options for Managing Insulin Dosing

Athena Philis-Tsimikas, MD The American Journal of Medicine

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

2018 Clinical Practice Guidelines In-Hospital Management of Diabetes

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Protocol for Management of Adult Patients with Diabetic Ketoacidosis

Insulin Delivery Systems Atlanta Diabetes Associates

Distribution of daily frequency of BGM

Postoperative blood glucose levels and total insulin requirement.

A: Glucose levels during basal-bolus and SSI treatment.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized, controlled study Featured Article: Guillermo E. Umpierrez, M.D., Roma Gianchandani, M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David H. Wesorick, M.D., Christopher Newton, M.D., Farnoosh Farrokhi, M.D., Limin Peng, P.H.D. David Reyes, M.D., Sangeeta Lathkar-Pradhan, M.B.B.S., Francisco Pasquel, M.D. Diabetes Care Volume 36: November, 2013

STUDY OBJECTIVE To investigate the safety and efficacy of sitagliptin (Januvia) for inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients Umpierrez G. E. et al. Diabetes Care 2013;36:

STUDY DESIGN AND METHODS T2D patients were randomized to receive sitagliptin alone or in combination with glargine insulin (glargine) or to a basal bolus insulin regimen (glargine and lispro) plus supplemental (correction) doses of lispro Major study outcomes: Differences in daily blood glucose (BG) Frequency of treatment failures (defined as three or more consecutive BG >240 mg/dL or a mean daily BG >240 mg/dL) Hypoglycemia between groups Umpierrez G. E. et al. Diabetes Care 2013;36:

RESULTS Glycemic control improved similarly in all treatment groups There were no differences in: Mean daily BG after the first day of treatment Number of readings within a BG target of 70 and 140 mg/dL Number of BG readings >200 mg/dL Number of treatment failures Total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group There were no differences in length of hospital stay or in the number of hypoglycemic events between groups Umpierrez G. E. et al. Diabetes Care 2013;36:

CONCLUSIONS Treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D Umpierrez G. E. et al. Diabetes Care 2013;36: